In breast cancer cells, AXL pathway activation results in decreased expression and presentation of MHC class I antigens, leading to the decreased tumour infiltration by CD4+ and CD8+ T cells, and consequently, immune evasion [75,76]. This evidence concerns the gene AXL and neoplasm.